topstockalerts
Oct 19, 9:14 PM
City Therapeutics, a Cambridge, Massachusetts-based clinical-stage biotech focused on RNA interference (RNAi) therapeutics, completed its IPO, raising approximately
$230 million in gross proceeds before underwriting discounts, commissions and other expenses. The company sold 12,777,777 shares of common stock at
$18 per share, including 1,666,666 shares issued after underwriters fully exercised their overallotment option. All shares were offered by the company.
The stock began trading on the Nasdaq Global Market on October 16, 2026, under its ticker, following the effectiveness of its registration statements on October 15. Goldman Sachs, Jefferies, Stifel and Oppenheimer acted as joint book-running managers.
City Therapeutics’ pipeline includes CITY-FXI, targeting thromboembolic diseases; CITY-RBP4, focused on Stargardt disease and other retinal disorders; and CITY-TFR2, aimed at treating anemia associated with chronic diseases.
$CTY
1 replies